NCT01784536View on ClinicalTrials.gov

Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Healthy
Interventions
DRUG

Single-Dose IV Oritavancin Diphosphate

Oritavancin will be administered as a single IV infusion. The infusion will last approximately 3 hours.

Trial Locations (1)

53095

Spaulding Clinical, West Bend

Sponsors
All Listed Sponsors
lead

Melinta Therapeutics, Inc.

INDUSTRY

NCT01784536 - Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers | Biotech Hunter | Biotech Hunter